Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Zalcberg, JR
Bishop, JF
Millward, MJ
Zimet, A
Laird, J
Barter, C
Seward, D
McKeage, MJ
Friedlander, ML
Toner, G
Berille, J
Blanc, C
机构：
[1] HEIDELBERG REPATRIAT HOSP,DEPT ONCOL,MELBOURNE,VIC 3081,AUSTRALIA
[2] HEIDELBERG REPATRIAT HOSP,DEPT THORAC MED,MELBOURNE,VIC 3081,AUSTRALIA
[3] PETER MACCALLUM CANC INST,DIV HAEMATOL & MED ONCOL,MELBOURNE,VIC 3002,AUSTRALIA
[4] PRINCE WALES HOSP,INST ONCOL,SYDNEY,NSW 2031,AUSTRALIA
[5] RHONE POULENC RORER,ANTONY,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1084 / 1084
页数：1
相关论文
共 50 条
  • [1] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC)
    Antón, A
    Díaz-Fernández, N
    Larriba, JG
    Vadell, C
    Masutti, B
    Montalar, J
    Barneto, I
    Artal, A
    Rosell, R
    [J]. LUNG CANCER, 1998, 22 (02) : 139 - 148
  • [4] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)-Final report
    Sovak, M. A.
    Guensch, L.
    Joyce, P.
    Lutzker, S. G.
    Schwartz, S.
    Shih, W. J.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Docetaxel-carboplatin chemotherapy in combination with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC): Interim results of the nonrandomized phase II study TaxErb
    Fischer, J. R.
    Griesinger, F.
    Fink, T.
    Buchholz, E.
    Salm, T.
    Marseille, A.
    Wolf, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)
    William, W. N., Jr.
    Kies, M. S.
    Fossella, F. V.
    Gladish, G.
    Heymach, J. V.
    Glisson, B. S.
    Tse, W. H.
    Liu, D.
    Herbst, R. S.
    Lippman, S. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] PRELIMINARY RESULTS OF INDUCTION CISPLATIN/DOCETAXEL FOLLOWED BY SHORT COURSE THORACIC RADIOTHERAPY AND CISPLATIN/DOCETAXEL OF CONSOLIDATION IN LOCALLY. ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PROSPECTIVE PHASE II TRIAL
    Genestreti, Giovenzio
    Piciucchi, Sara
    Romeo, Antonino
    Parisi, Elisabetta
    Monti, Manuela
    Giovannini, Noemi
    Poletti, Venerino
    Matteucci, Federica
    Polico, Rolando
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1268 - S1269
  • [8] Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: Interim analysis
    Belani, C
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (03) : 10 - 14
  • [9] Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer
    Belani, CP
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 4 - 9
  • [10] A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
    E. Kontopodis
    A. Kotsakis
    N. Kentepozidis
    K. Syrigos
    N. Ziras
    M. Moutsos
    G. Filippa
    A. Mala
    L. Vamvakas
    D. Mavroudis
    V. Georgoulias
    S. Agelaki
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 77 : 949 - 956
12345